Albuterol/budesonide (Airsupra) has now proven effective as novel combination as-needed rescue medication for adults with asthma regardless of disease severity.
A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.
Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.
The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.
Your daily dose of the clinical news you may have missed.
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
The additional indication for benralizumab was supported by data from the phase 3 TATE trial.
The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
Your daily dose of the clinical news you may have missed.
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.